

Orchid Chemicals & Pharmaceuticals Ltd.

UNAUDITED FINANCIAL RESULTS FOR THREE MONTHS ENDED DECEMBER 31, 2013

					(Rs.Lakhs)
S.No	Particular	Standalone			
		Unaudited			Audited
		Three months ended 31-Dec-13	Three months ended 30-Sep-13	Three months ended 31-Dec-12	Eighteen months ended 30-Sep-13
1	Net Sales/Income from Operations (Net of Excise Duty)	36,881.97	37,725.00	31,352.96	185,357.71
2	Other operating Income	278.08	321.84	-	5,314.05
3	Total Operating Income (1+2)	37,160.05	38,046.84	31,352.96	190,671.76
4	Expenditure				
	a) Cost of materials consumed	15,763.18	22,615.13	9,352.92	82,246.39
	b) Purchases of stock-in-trade	120.00	(278.37)	1,370.12	5,099.37
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,290.49)	(3,998.55)	6,613.47	8,481.03
	d) Employees cost	3,294.09	2,995.68	4,084.56	22,631.26
	e) Depreciation/Amortisation	5,740.73	4,476.30	3,906.01	24,386.86
	f) Other Expenditure	8,324.09	17,313.54	7,596.62	55,253.37
	g) Total	31,951.60	43,123.73	32,923.70	198,098.28
5	Profit/(Loss) from Operations before Other Income, Interest, Exceptional Item (3-4)	5,208.45	(5,076.89)	(1,570.74)	(7,426.52)
6	Other Income	0.16	-	-	1.31
7	Profit/(Loss) before Interest & Exceptional Item (5+6)	5,208.61	(5,076.89)	(1,570.74)	(7,425.21)
8	Finance cost	9,555.79	12,088.28	7,069.30	52,038.06
9	Profit/(loss) after interest but before Exceptional Item (7-8)	(4,347.18)	(17,165.17)	(8,640.04)	(59,463.27)
10	Exceptional Item - Gain/(Loss)	(1,043.06)	(1,469.53)	(559.18)	5,111.08
11	Profit/(Loss) before Tax (9+10) from Ordinary activities	(5,390.24)	(18,634.70)	(9,199.22)	(54,352.19)
12	Tax expenses				
	- Current Tax & Deferred Tax	-	1,400.02	(1,963.45)	(1,329.56)
13	Net Profit/(Loss) after Tax (11-12)	(5,390.24)	(20,034.72)	(7,235.77)	(53,022.63)
14	Paid-up Equity Share Capital (Face value of Rs.10/- each)	7,045.21	7,045.21	7,045.21	7,045.21
15	Reserves excluding Revaluation Reserves	-	-	-	41,771.33
16	Earnings per share (EPS) before extra-ordinary item				
	- Basic Rs.*	(7.65)	(28.44)	(10.27)	(75.26)
	- Diluted Rs.*	(7.65)	(28.44)	(10.27)	(75.26)
17	Earnings per share (EPS) after extra-ordinary item				
	- Basic Rs.*	(7.65)	(28.44)	(10.27)	(75.26)
	- Diluted Rs.*	(7.65)	(28.44)	(10.27)	(75.26)
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of equity shares	47,711,295	47,711,295	47,611,295	47,711,295
	- Percentage of Shareholding	67.72	67.72	67.58	67.72
2	Promoters and Promoter group shareholding				
	a. Pledged/Encumbered				
	- Number of shares	17,276,400	18,941,608	17,818,645	18,941,608
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	75.97	83.29	78.01	83.29
	- Percentage of shares (as a % of the total share capital of the company)	24.52	26.89	25.29	26.89
	b. Non - Encumbered				
	- Number of shares	5,464,381	3,799,173	5,022,136	3,799,173
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	24.03	16.71	21.99	16.71
	- Percentage of shares (as a % of the total share capital of the company)	7.76	5.39	7.13	5.39
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter			-NIL-	
	Received during the quarter			4	
	Disposed of during the quarter			4	
	Remaining unresolved at the end of the quarter			-NIL-	
	* EPS for the period is not annualised				
1	The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 11, 2014 and have been subjected to limited review by the statutory auditors.				
2	The Company is operating in single segment (i.e) "Pharmaceuticals".				
3	The Company's application for Debt Restructuring has been admitted by the CDR Empowered Group and final approval for the restructuring package is expected before end of February 2014.				
4	The Company has entered into a Business Transfer Agreement (BTA) dated August 29, 2012 with Hospira Healthcare India Private Limited for the sale and transfer of Orchid's Penicillin and Penem API business and the API facility located in Aurangabad (Maharashtra) together with an associated Process R&D infrastructure located in Chennai. The Business Transfer is likely to get completed after the approval of the CDR package and accordingly provision for taxation has been made on the assumption that the Business Transfer will be completed before March 31, 2014.				
5	Exceptional items for three months ended December 31,2013 represents amortisation of exchange loss on restatement of Foreign currency loans.				
6	The Company had exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated March 31, 2009. The Ministry of Corporate affairs vide notification dated 29/12/2011 has extended the amortisation of gains or losses arising on reporting of foreign currency monetary items over the balance period of such long term asset/liability. Accordingly exchange loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortised in the financial statements as at December 31, 2013 on account of exercising the above option is Rs.15427.18 Lakhs.				
7	The auditors have observed matters relating to recovery of certain advances paid to suppliers, non-provision of diminution in value of investments in a foreign R&D subsidiary and non-provision of penal interest on loans taken by the Company. The Company has already been admitted for Corporate Debt Restructuring scheme and the final approval for the scheme is expected before end of February 2014. Due to financial constraints, the Company was not able to take delivery of materials/capital goods and the company is confident that with the CDR approval, the company would be able to take delivery of these materials in due course. As far as the diminution in value of investments is concerned, the Company is confident that the value of molecules held by the foreign subsidiary will be more than the investment. With the approval for the CDR scheme, the interest liability will come down and hence there will be no need for any provision for penal interest. The management confirms that there will be no impact on the financials on account of the matters referred to in the audit report.				
8	Previous period figures have been regrouped wherever necessary.				
For and on behalf of the Board					
Place: Chennai			K. Raghavendra Rao		
Date : February 11, 2014			Chairman & Managing Director		